Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

Presentation AHA 2023

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Presenter: Dike Ojji

November 17, 2023

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation AHA 2023

MINT: Myocardial Ischemia and Transfusion

Presenter: Jeffrey L Carson

November 13, 2023

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

Presentation AHA 2023

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

Presenter: Demilade Adedinsewo

November 13, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

Presentation SCCT 2023

ACC/AHA Guidelines (with emphasis on stable patients) A critical appraisal

Presenter: Andrew Kelion

July 28, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation TCT 2022

Case 2: COVID Patient With Clot in Transit

Presenter: Matthew Finn

September 18, 2022

Presentation TCT 2022

Novel Devices to Treat Hypertension: What Else Should We Expect in the Near Future?

Presenter: Felix Mahfoud

September 17, 2022

Presentation TCT 2022

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Presenter: Naomi Fisher

September 17, 2022

Presentation TCT 2022

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Presenter: David Kandzari

September 17, 2022

Presentation TCT 2022

Novel Approaches to Assess Hypertension Control Outside the Office

Presenter: Naomi Fisher

September 17, 2022

Presentation TCT 2022

Combination Therapy and Patient Outreach to Improve Adherence to Pharmacotherapies

Presenter: Melvin Lobo

September 17, 2022

Advertisement

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

MINT: Myocardial Ischemia and Transfusion

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

ACC/AHA Guidelines (with emphasis on stable patients) A critical appraisal

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Case 2: COVID Patient With Clot in Transit

Novel Devices to Treat Hypertension: What Else Should We Expect in the Near Future?

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Novel Approaches to Assess Hypertension Control Outside the Office

Combination Therapy and Patient Outreach to Improve Adherence to Pharmacotherapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content